Study of risvutatug rezetecan for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests an experimental drug called Risvutatug Rezetecan for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The drug works by targeting cancer cells and delivering a toxic agent directly to them, potentially slowing the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have a type of prostate cancer called adenocarcinoma that has spread to other parts of the body
- You must be able to manage your daily activities with little or no help (this is called an ECOG score of 0 or 1)
- Your life expectancy must be at least 4 months
- Your liver, kidneys, and other organs must work well enough
- You cannot have received certain types of targeted therapy called 'ADC with topoisomerase inhibitor' in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs—ruxolitinib and enzalutamide—together to see if they can help men whose prostate cancer has spread and stopped responding to abiraterone. It is for those whose cancer grew quickly on abiraterone.
This trial tests a new pill, Rezvilutamide, for men with prostate cancer that was removed by surgery but has features that make it more likely to come back. It's an alternative for those who don't want or can't have radiation therapy after surgery.
This trial tests a new drug, rezvilutamide, combined with standard hormone therapy for men with prostate cancer that has spread but still responds to hormone treatment. The goal is to see if this drug helps control the cancer longer than the usual treatment alone.
This trial tests a combination of two oral drugs, relugolix and enzalutamide, in men with high-risk prostate cancer that hasn't spread to distant parts of the body. The goal is to see if this treatment can help control the cancer before or alongside local therapies like surgery or radiation.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a new drug, HRS-4357, against standard treatments for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see if the new drug works better.
Hear when a new Neoplasms, Prostate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.